Standverwaltung
Option auswählen

Fluxergy, Inc.

13766, Alton Parkway Suite 150, 92618 Irvine, CA
USA
Telefon +1 949 3054201206
Fax +1 949 3051388
info@fluxergy.com

Kontaktdaten an Aussteller übermittlen

Übermitteln Sie dem Aussteller Ihre Kontaktdaten. Optional können Sie eine persönliche Nachricht ergänzen.

Bitte einloggen

Sie müssen angemeldet sein, um die Kontaktanfrage zu senden.

Ein Fehler ist aufgetreten

Bitte überprüfen Sie Ihre Internetverbindung oder versuchen Sie es zu einem späteren Zeitpunkt noch einmal.

Nachricht erfolgreich gesendet

Ihre Nachricht an den Aussteller wurde erfolgreich gesendet.

Mediendateien des Ausstellers

Ansprechpartner

Dr. Ali Tinazli

Chief Commercial Officer

13766 Alton Parkway
92618 Irvine, USA

Telefon
+13104671112

E-Mail
atinazli@fluxergy.com

Besuchen Sie uns!

Noch offen / NN

16.11.2020

Thema

ganztägig

Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*

The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests with patient samples by researchers at University of California San Diego (UCSD).

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Mehr Weniger

ganztägig

How the Coronavirus SARS-CoV-2 Exposes the Flaws of Current Health Testing

The rapid spread of COVID-19, which has the potential to become a once-in-a-century pandemic,
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Mehr Weniger

17.11.2020

Thema

ganztägig

Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*

The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests with patient samples by researchers at University of California San Diego (UCSD).

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Mehr Weniger

ganztägig

How the Coronavirus SARS-CoV-2 Exposes the Flaws of Current Health Testing

The rapid spread of COVID-19, which has the potential to become a once-in-a-century pandemic,
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Mehr Weniger

18.11.2020

Thema

ganztägig

Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*

The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests with patient samples by researchers at University of California San Diego (UCSD).

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Mehr Weniger

ganztägig

How the Coronavirus SARS-CoV-2 Exposes the Flaws of Current Health Testing

The rapid spread of COVID-19, which has the potential to become a once-in-a-century pandemic,
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Mehr Weniger

19.11.2020

Thema

ganztägig

Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*

The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests with patient samples by researchers at University of California San Diego (UCSD).

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Mehr Weniger

ganztägig

How the Coronavirus SARS-CoV-2 Exposes the Flaws of Current Health Testing

The rapid spread of COVID-19, which has the potential to become a once-in-a-century pandemic,
has demonstrated that current diagnostic testing methodology is too slow and too inaccessible
to address today’s dramatically changing healthcare challenges. New technologies are needed
immediately that provide fast, accurate, and low-cost tests directly at the Point of Care.

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Mehr Weniger

Unser Angebot

Produktkategorien

  • 03  Diagnostika
  • 03.01  Klinische Chemie
  • 03.01.03  Harndiagnostik, Geräte und Systeme für die

Harndiagnostik, Geräte und Systeme für die

  • 03  Diagnostika
  • 03.01  Klinische Chemie
  • 03.01.04  Schnelltests in der klinischen Chemie

Schnelltests in der klinischen Chemie

  • 03  Diagnostika
  • 03.02  Immunochemie / Immunologie
  • 03.02.01  Immun-Assay-Systeme

Immun-Assay-Systeme

  • 03  Diagnostika
  • 03.02  Immunochemie / Immunologie
  • 03.02.02  Diagnose-Schnelltests
  • 03  Diagnostika
  • 03.03  Hämatologie / Histologie / Zytologie
  • 03.03.04  Sonstige Geräte und Tests zur Hämatologie / Histologie / Zytologie

Sonstige Geräte und Tests zur Hämatologie / Histologie / Zytologie

  • 03  Diagnostika
  • 03.04  Mikrobiologie-Tests
  • 03.04.03  Schnelltests in der Mikrobiologie
  • 03  Diagnostika
  • 03.05  Infektionsimmunologie
  • 03.05.02  Mikrobiologische Diagnostik / Virologie, Geräte und Systeme für die

Mikrobiologische Diagnostik / Virologie, Geräte und Systeme für die

  • 03  Diagnostika
  • 03.06  Gentests, molekularbiologische Diagnostik
  • 03.06.01  DNA-Tests
  • 03  Diagnostika
  • 03.06  Gentests, molekularbiologische Diagnostik
  • 03.06.02  Molekulare Biomarker
  • 03  Diagnostika
  • 03.06  Gentests, molekularbiologische Diagnostik
  • 03.06.03  Polymerase chain reaction (PCR)
  • 06  Informationstechnik und Kommunikationstechnik
  • 06.02  mHealth, mobile IT, kabellose Technologien (wireless, Bluetooth, W-LAN)

mHealth, mobile IT, kabellose Technologien (wireless, Bluetooth, W-LAN)

  • 06  Informationstechnik und Kommunikationstechnik
  • 06.04  eHealth, Telemedizin / Telematik / Telemetrie

Unsere Produkte

Produktkategorie: Diagnose-Schnelltests, Schnelltests in der Mikrobiologie, Polymerase chain reaction (PCR), Mikrobiologische Diagnostik / Virologie, Geräte und Systeme für die, DNA-Tests, Molekulare Biomarker, mHealth, mobile IT, kabellose Technologien (wireless, Bluetooth, W-LAN), eHealth, Telemedizin / Telematik / Telemetrie

Fluxergy COVID-19 Sample-to-Answer RT-PCR Test*

The Fluxergy Analyzer system is a testing platform designed for multiplex, multimodal assays*. Fluxergy’s CoVID-19-Sample-to-Answer-RT-PCR test, which utilizes state-of-the-art PCR and microfluidics technology, has been shown to identify the
SARS-CoV-2 virus in under one hour in bench lab tests performed by both internal studies and in follow-up validation tests
with patient samples by researchers at University of California San Diego (UCSD).

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities
are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future evenets could differ materially from those anticipated in such statements.

Mehr Weniger

Produktkategorie: Polymerase chain reaction (PCR), Diagnose-Schnelltests, Harndiagnostik, Geräte und Systeme für die, Schnelltests in der klinischen Chemie, Immun-Assay-Systeme, Sonstige Geräte und Tests zur Hämatologie / Histologie / Zytologie, Schnelltests in der Mikrobiologie, Mikrobiologische Diagnostik / Virologie, Geräte und Systeme für die, DNA-Tests, Molekulare Biomarker, mHealth, mobile IT, kabellose Technologien (wireless, Bluetooth, W-LAN), eHealth, Telemedizin / Telematik / Telemetrie

Fluxergy Analyzer Platform*

Our core device, the Fluxergy Analyzer, is a highly-integrated sensor system along with our sophisticated analysis algorithms. The Fluxergy Analyzer can be used for laboratory analyses such as PCR, ELISA, ISE, and cytometry-based assays.

Ruggedized Exterior Casing
The Fluxergy Analyzer features a smooth monocoque casing that is both lightweight and robust.

Active Cooling System
The active cooling system allows the Fluxergy Analyzer to rapidly manipulate the subjected sample to significantly decrease test times.

Quick Battery Hookup
Whether you are in a resource-limited setting or at a high-tech laboratory, the Fluxergy Analyzer can always have power. Simply hook up a compatible battery pack and realize the portability of the Fluxergy Analyzer system.

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities
are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future evenets could differ materially from those anticipated in such statements.

Mehr Weniger

Firmennews

Datum

Thema

Download

30.06.2020

Fluxergy, Mass General Brigham Partner to Evaluate Rapid COVID-19 Molecular Testing System

Mehr Weniger

29.06.2020

Fluxergy to Collaborate With Mass General Brigham to Conduct Evaluation of One-Hour COVID-19 Diagnostic Test

Mehr Weniger

Über uns

Firmenporträt

Das 2013 gegründete Unternehmen Fluxergy hat sich zum Ziel gesetzt, eine tragbare, einfach zu bedienende Probe-zu-Antwort-Plattform bereitzustellen, die es Klinikern ermöglicht, eine breite Palette anspruchsvoller Multiplex- und multimodaler In-vitro-Diagnosetests (verschiedene Testarten auf einmal, bis zu 30 Ziele) am Point-of-Care kostengünstig durchzuführen.

Das Fluxergy-Diagnosetestsystem besteht aus der Fluxergy Card, einer Einweg-Lab-on-Chip"-Testkassette für Verbrauchsmaterial; dem Fluxergy Analyzer, der den Testprozess durchführt, und der FluxergyWorks-Software, die vom Kliniker/Bediener zur Überprüfung und Interpretation der Testdaten verwendet wird. Die Fluxergy-Karten sind so konzipiert, dass sie sehr kosteneffektiv und skalierbar sind, wobei proprietäre Technologien zur Herstellung von Leiterplatten (PCB) und Mikrofluidik zum Einsatz kommen. FluxergyWorks ermöglicht es Organisationen, bis zu 256 Fluxergy-Analysatoren für eine zentralisierte Datenauswertung über die Cloud miteinander zu verbinden.

Bitte besuchen Sie fluxergy.com für weitere Informationen.

Kontakt: Dr. Ali Tinazli, atinazli@fluxergy.com

*Fluxergy’s products are for Research Use Only (RUO) and are not for use in diagnostic procedures. Fluxergy’s products are not yet cleared by the FDA or USDA for in vitro diagnostic use. None of these statements have been endorsed by the FDA or USDA. Fluxergy does not currently sell products for human or food use. Although forward-looking statements contained in this document regarding Fluxergy’s objectives, plans, goals, strategies, future growth, business prospects and opportunities are based upon what Fluxergy management believes are reasonable assumptions, estimates, and other judgments, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Mehr Weniger

Unternehmensdaten

Anzahl der Beschäftigten

50-99

Gründungsjahr

2013

Geschäftsfelder
  • Elektromedizin / Medizintechnik
  • Labortechnik
  • Diagnostika